Imfinzi significantly improves overall survival in the Phase III
PACIFIC trial for unresectable Stage III non-small cell lung cancer
Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis
https://www.investegate.co.uk/astrazene ... 00062684P/